Fig. 1.

Ruxolitinib treatment improved liver pathology in ARE-Del^+/− mice. A The treatment protocol utilized in the treatment of ARE-Del^+/− mice. Groups of mice were injected intraperitoneally with either ruxolitinib or the control carrier DMSO. B Representative liver and spleen mononuclear cell counts in ruxolitinib-treated (n = 11) and control group mice (n = 10). C Graphical summary of the histological scores of disease severity between the treatment (n = 11) and control groups (n = 8). D Representative displays of H&E-assisted liver pathology from the treatment and control groups (original magnification ×40). *p < 0.05, **p < 0.01, ***p < 0.001. → Lymphocyte infiltration in the portal and biliary ducts is significantly reduced in treated mice compared with control mice